Safety and Tolerability of VK2809 in Patients With Primary Hypercholesterolemia and Non-Alcoholic Fatty Liver Disease
Status:
Completed
Trial end date:
2019-03-26
Target enrollment:
Participant gender:
Summary
This study will investigate the efficacy, safety, and tolerability of VK2809 in lowering
LDL-C and liver fat content in patients with primary hypercholesterolemia and fatty liver
disease. The primary efficacy endpoint is percent change from baseline LDL-C at the end of
the treatment period (Week 12). Secondary endpoints include effects on liver fat content and
other liver and lipid markers, as well as effects on safety and tolerability, and
pharmacokinetic (PK) measurements.